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........................... 
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IMPORTANT 
Please refer to the guidance for ‘Completing the ISAC application form’ found on 
the CPRD website (www.cprd.com/isac). If you have any queries, please 
contact the ISAC Secretariat at isac@cprd.com. 
 
 
SECTION A: GENERAL INFORMATION ABOUT THE PROPOSED RESEARCH STUDY 
 
1. Study Title§ (Please state the study title below) 
The effect of renin-angiotensin system inhibitors on haemoglobin 
 
§Please note: This information will be published on the CPRD’s website as part of its transparency policy.  
2. Has any part of this research proposal or a related proposal been previously submitted to ISAC?  
Yes *   No   
 
*If yes, please provide the previous protocol number/s below. Please also state in your current submission how this/these are related 
or relevant to this study. 
 N/A 
 
3. Has this protocol been peer reviewed by another Committee? (e.g. grant award or ethics committee) 
Yes*    No   
 
*If Yes, please state the name of the reviewing Committee(s)  below and provide an outline of the review process and outcome as an 
Appendix to this protocol : N/A 
 
4. Type of Study (please tick all the relevant boxes which apply) 
 
Adverse Drug Reaction/Drug Safety    Drug Effectiveness                                
Drug Utilisation                 Pharmacoeconomics       
Disease Epidemiology       Post-authorisation Safety                         
Health care resource utilisation      Methodological  Research                                     
Health/Public Health Services Research               Other*                                                                                   
  
*If Other, please specify the type of study here and in the lay summary below: 
 
5. Health Outcomes to be Measured§ 
§Please note: This information will be published on CPRD’s website as part of its transparency policy.  
 
Please summarise below the primary/secondary health outcomes to be measured in this research protocol: 
 
 
• Change in haemoglobin 
level (primary outcome)    
• Bone marrow suppression 
(secondary outcome)                               
•        
•          •               •        
•              •        •        
 
[Please add more bullet points as necessary] 
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6. Publication: This study is intended for (please tick all the relevant boxes which apply): 
 
Publication in peer-reviewed journals   Presentation at scientific conference  
Presentation at company/institutional meetings  Regulatory purposes    
Other*       
 
*If Other, please provide further information: N/A 
SECTION B: INFORMATION ON INVESTIGATORS AND COLLABORATORS 
 
7. Chief Investigator§  
Please state the full name, job title, organisation name & e-mail address for correspondence - see guidance notes for eligibility. Please 
note that there can only be one Chief Investigator per protocol.  
Laurie Tomlinson, Associate Professor, London School of Hygiene & Tropical Medicine 
laurie.tomlinson@lshtm.ac.uk 
 
§Please note: The name and organisation of the Chief Investigator and  will be published on CPRD’s website as part of its transparency policy  
 
CV has been previously submitted to ISAC    CV number:  271_15CESL 
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
 
8. Affiliation of Chief Investigator (full address) 
 
Department of Non-Communicable Disease Epidemiology 
London School of Hygiene & Tropical Medicine 
Keppel Street 
London 
WC1E 7HT 
 
9. Corresponding Applicant§ 
Please state the full name, affiliation(s) and e-mail address below: 
Kathryn Mansfield, London School of Hygiene & Tropical Medicine 
kathryn.mansfield@lshtm.ac.uk 
 
§Please note: The name and organisation of the corresponding applicant and their organisation  name will be published on CPRD’s website as part of its 
transparency policy 
 
Same as chief investigator       
CV has been previously submitted to ISAC    CV number:  319_15S 
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
 
10. List of all investigators/collaborators§  
Please list the full name, affiliation(s) and e-mail address* of all collaborators, other than the Chief Investigator below: 
 
§Please note: The name of all investigators and their organisations/institutions will be published on CPRD’s website as part of its transparency policy 
 
Other investigator: Kathryn Mansfield, LSHTM, kathryn.mansfield@lshtm.ac.uk 
CV has been previously submitted to ISAC    CV number:  319_15S 
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
 
Other investigator: Dorothea Nitsch, LSHTM, dorothea.nitsch@lshtm.ac.uk 
CV has been previously submitted to ISAC    CV number:  321_15CESL 
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
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Other investigator: Liam Smeeth, LSHTM, liam.smeeth@lshtm.ac.uk 
CV has been previously submitted to ISAC    CV number:  045_15CEPSL 
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
 
Other investigator: Masao Iwagami, LSHTM, masao.iwagami@lshtm.ac.uk 
CV has been previously submitted to ISAC    CV number:  318_15S 
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
 
Other investigator: Rosalynd Johnston, Royal Sussex County Hospital, Rosalynd.Johnston@bsuh.nhs.uk 
CV has been previously submitted to ISAC    CV number:        
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
 
[Please add more investigators as necessary] 
 
*Please note that your ISAC application form and protocol must be copied to all e-mail addresses listed above at the time of submission of your 
application to the ISAC mailbox. Failure to do so will result in delays in the processing of your application. 
 
11. Conflict of interest statement*  
Please provide a draft of the conflict (or competing) of interest (COI) statement that you intend to include in any publication which 
might result from this work 
The authors declare no conflict of interest for the submitted work; no financial relationships with any organisations that 
might have an interest in the submitted work in the previous three years; and no other relationships or activities that 
could appear to have influenced the submitted work. 
 
*Please refer to the International Committee of Medical Journal Editors (ICMJE) for guidance on what constitutes a COI. 
 
12. Experience/expertise available  
Please complete the following questions to indicate the experience/ expertise available within the team of investigators/collaborators 
actively involved in the proposed research, including the analysis of data and interpretation of results. 
 
 Previous GPRD/CPRD Studies  Publications using GPRD/CPRD data 
None                        
1-3                         
> 3                         
 
Experience/Expertise available  Yes No 
Is statistical expertise available within the research team? 
If yes, please indicate the name(s) of the relevant investigator(s)   
 Dorothea Nitsch  
  
Is experience of handling large data sets (>1 million records) available within the 
research team? 
If yes, please indicate the name(s) of the relevant investigator(s) 
 Kathryn Mansfield, Laurie Tomlinson, Dorothea Nitsch, Liam Smeeth, Masao Iwagami 
  
Is experience of practising in UK primary care available to or within the research 
team? 
If yes, please indicate the name(s) of the relevant investigator(s)  
 Liam Smeeth 
  
13. References relating to your study 
Please list up to 3 references (most relevant) relating to your proposed study:  
1. Cheungpasitporn W, Thongprayoon C, Chiasakul T, Korpaisarn S, Erickson SB. Renin-angiotensin system 
inhibitors linked to anemia: A systematic review and meta-analysis. QJM 2015; 108: 879–84. 
2. Mikolasevic I, Zaputovic L, Zibar L, et al. Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and 
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hematocrit only in renal transplant recipients with initially higher levels. Eur J Intern Med 2016; 29: 98–103. 
3. Ajmal A, Gessert CE, Johnson BP, Renier CM, Palcher JA. Effect of angiotensin converting enzyme inhibitors and 
angiotensin receptor blockers on hemoglobin levels. BMC Res Notes 2013; 6: 443. 
SECTION C: ACCESS TO THE DATA  
 
14. Financial Sponsor of study§ 
§Please note: The name of the source of funding will be published on CPRD’s website as part of its transparency policy 
 
Pharmaceutical Industry            Please specify name and country:      
Academia              Please specify name and country:      
Government / NHS             Please specify name and country:      
Charity              Please specify name and country: Wellcome Trust 
Other              Please specify name and country:      
None    
 
15. Type of Institution conducting the research 
 
Pharmaceutical Industry             Please specify name and country:      
Academia               Please specify name and country: LSHTM, UK 
Government Department             Please specify name and country:      
Research Service Provider             Please specify name and country:      
NHS               Please specify name and country:      
Other               Please specify name and country:      
16. Data access arrangements 
 
The financial sponsor/ collaborator* has a licence for CPRD GOLD and will extract  the data                               
The institution carrying out the analysis has a licence for CPRD GOLD and will extract the data**         
A data set will be provided by the CPRD¥€             
CPRD has been commissioned to extract the data and perform the analyses€                                         
Other:           
If Other, please specify: N/A  
 
*Collaborators supplying data for this study must be named on the protocol as co-applicants. 
**If data sources other than CPRD GOLD are required, these will be supplied by CPRD 
¥Please note that datasets provided by CPRD are limited in size; applicants should contact CPRD (enquiries@cprd.com) if a dataset of >300,000 patients 
is required. 
€Investigators must discuss their request with a member of the CPRD Research team before submitting an ISAC application. Please contact the CPRD 
Research Team on +44 (20) 3080 6383 or email (enquiries@cprd.com) to discuss your requirements. Please  also state the name of CPRD Research team 
with whom you have discussed this request (provide the date of discussion and any relevant reference information):   
 
 Name of CPRD Researcher   N/A       Reference number (where available) N/A      Date of contact N/A    
17. Primary care data  
Please specify which primary care data set(s) are required) 
Vision only (Default for CPRD studies                       Both Vision and EMIS®*            
EMIS® only*          
       
Note: Vision and EMIS are different practice management systems. CPRD has traditionally collected data from Vision practice. Data collected from EMIS 
is currently under evaluation prior to wider release.  
*Investigators requiring the use of EMIS data must discuss the study with a member of the CPRD Research team before submitting an ISAC application 
 
Please state the name of the CPRD Researcher with whom you have discussed your request for EMIS data: 
Name of CPRD Researcher N/A     Reference number (where available) N/A    Date of contact N/A    
 
SECTION D: INFORMATION ON DATA LINKAGES 
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18. Does this protocol seek access to linked data 
 
Yes*   No          If No, please move to section E. 
 
*Research groups which have not previously accessed CPRD linked data resources must discuss access to these resources with a member of the CPRD 
Research team, before submitting an ISAC application. Investigators requiring access to HES Accident and Emergency data, HES Diagnostic Imaging 
Dataset PROMS data and the Pregnancy Register must also discuss this with a member of the CPRD Research team before submitting an ISAC 
application. Please contact the CPRD Research Team on +44 (20) 3080 6383 or email enquiries@cprd.com to discuss your requirements before 
submitting your application. 
 
Please state the name of the CPRD Researcher with whom you have discussed your linkage request.  
 
Name of CPRD Researcher Tarita Murray-Thomas      Reference number (where available) CPRD00010290      Date of 
contact 18th July 2017    
 
Please note that as part of the ISAC review of linkages, your protocol may be shared - in confidence - with a representative of the requested linked data 
set(s) and summary details may be shared - in confidence - with the Confidentiality Advisory Group of the Health Research Authority.  
 
19. Please select the source(s) of linked data being requested§ 
§Please note: This information will be published on the CPRD’s website as part of its transparency policy.  
 
 ONS Death Registration Data                              MINAP (Myocardial Ischaemia National Audit Project)   
 HES Admitted Patient Care                   Cancer Registration Data* 
 HES Outpatient                                      PROMS (Patient Reported Outcomes Measure)** 
 HES Accident and Emergency               CPRD Mother Baby Link 
 HES Diagnostic Imaging Dataset           Pregnancy Register 
  
 Practice Level Index of Multiple Deprivation (Standard) 
 Practice Level Index of Multiple Deprivation (Bespoke) 
 Patient Level Index of Multiple Deprivation*** 
 Patient Level Townsend Score *** 
 Other**** Please specify:      
 
*Applicants seeking access to cancer registration data must complete a Cancer Dataset Agreement form (available from CPRD). This should be 
submitted to the ISAC as an appendix to your protocol. Please also note that applicants seeking access to cancer registry data must provide consent for 
publication of their study title and study institution on the UK Cancer Registry website.  
**Assessment of the quality of care delivered to NHS patients in England undergoing four procedures: hip replacement, knee replacement, groin hernia 
and varicose veins. Please note that patient level PROMS data are only accessible by academics 
*** ‘Patient level IMD and Townsend scores will not be supplied for the same study 
****If “Other” is specified, please provide the name of the individual in the CPRD Research team with whom this linkage has been discussed.  
 
Name of CPRD Researcher N/A     Reference number (where available) N/A     Date of contact N/A    
 
20. Total number of linked datasets requested including CPRD GOLD  
Number of linked datasets requested (practice/ ’patient’ level Index of Multiple Deprivation, Townsend Score, the CPRD Mother Baby Link 
and the Pregnancy Register should not be included in this count)  3 (CPRD GOLD + HES APC + HES outpatient) 
 
Please note:  Where ≥5  linked datasets are requested, approval may be required from the Confidentiality Advisory Group (CAG) to access these data 
21. Is linkage to a local¥ dataset with <1 million patients being requested?  
 
Yes *   No   
 
 *If yes, please provide further details: N/A 
¥ Data from defined geographical areas i.e. non-national datasets. 
 
22. If you have requested one or more linked data sets, please indicate whether the Chief Investigator or any of the 
collaborators listed in question 5 above, have access to these data in a patient identifiable form (e.g. full date of 
birth, NHS number, patient post code), or associated with an identifiable patient index. 
 
Yes*             No   
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* If yes, please provide further details: N/A 
 
23. Does this study involve linking to patient identifiable data (e.g. hold date of birth, NHS number, patient post code) 
from other sources? 
 
Yes    No   
 
SECTION E: VALIDATION/VERIFICATION 
 
24. Does this protocol describe a purely observational study using CPRD data? 
 
Yes*    No**   
 
 * Yes: If you will be using data obtained from the CPRD Group, this study does not require separate ethics approval from an NHS Research Ethics 
Committee. 
** No: You may need to seek separate ethics approval from an NHS Research Ethics Committee for this study. The ISAC will provide advice on whether 
this may be needed. 
 
25. Does this protocol involve requesting any additional information from GPs?  
 
Yes*    No   
 
 * If yes, please indicate what will be required:  
 
  Completion of questionnaires by the GP        Yes         No  
     Is the questionnaire a validated instrument?                                              Yes         No  
     If yes, has permission been obtained to use the instrument?                     Yes        No   
     Please provide further information:       
 
  Other (please describe)       
 
 Any questionnaire for completion by GPs or other health care professional must be approved by ISAC before circulation for completion.  
  
26. Does this study require contact with patients in order for them to complete a questionnaire? 
 
Yes*    No   
 
*Please note that any questionnaire for completion by patients must be approved by ISAC before circulation for completion.  
 
27. Does this study require contact with patients in order to collect a sample? 
 
Yes*    No   
 
* Please state what will be collected: N/A   
 
SECTION F: DECLARATION 
 
28. Signature from the Chief Investigator 
 
 I have read the guidance on ‘Completion of the ISAC application form’ and ‘Contents of CPRD ISAC Research Protocols’ and have 
understood these; 
 I have read the submitted version of this research protocol, including all supporting documents, and confirm that these are 
accurate.  
 I am suitably qualified and experienced to perform and/or supervise the research study proposed. 
 I agree to conduct or supervise the study described in accordance with the relevant, current protocol  
 I agree to abide by all ethical, legal and scientific guidelines that relate to access and use of CPRD data for research  
 I understand that the details provided in sections marked with (§) in the application form and protocol will be published on the 
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CPRD website in line with CPRD’s transparency policy. 
 I agree to inform the CPRD of the final outcome of the research study: publication, prolonged delay, completion or termination of 
the study. 
 
Name: Laurie Tomlinson  Date: 3rd Aug 2017              e-Signature (type name):  Laurie Tomlinson 
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PROTOCOL INFORMATION REQUIRED 
 
Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
A. Study Title§ 
§Please note: This information will be published on CPRD’s website as part of its transparency policy 
 
The effect of renin-angiotensin system inhibitors on haemoglobin 
B. Lay Summary (Max. 200 words)§ 
§Please note: This information will be published on CPRD’s website as part of its transparency policy 
Angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are drugs that 
are commonly used to treat high blood pressure and heart failure. Haemoglobin is the molecule in red 
blood cells that carries oxygen from the lungs to the body. When there is not enough haemoglobin in the 
blood (anaemia) people experience symptoms like fatigue, weakness and shortness of breath. Anaemia 
can also worsen heart and kidney disease, and is associated with increased risk of death. There is some 
evidence to suggest that ACEI/ARB drugs cause anaemia. Our study therefore aims to investigate the 
effect of starting ACEI/ARB drugs on haemoglobin levels, using a comparison drug (calcium channel 
blockers). We will also investigate whether the effect of ACEI/ARB drugs on anaemia is influenced by 
either: the patient’s haemoglobin level prior to starting the drug, or their kidney function (the kidneys 
produce a hormone that controls red blood cell production). This information would help improve 
prescribing guidelines for these drugs, offer insight into their risks and benefits, and help identify those 
needing careful haemoglobin monitoring when starting on ACEI/ARBs. 
C. Technical Summary (Max. 200 words)§ 
§Please note: This information will be published on CPRD’s website as part of its transparency policy 
We aim to investigate the association between ACEI/ARBs and reduction in haemoglobin. We will 
identify a cohort of new-users of ACEI/ARBs and calcium channel blockers (CCB) with haemoglobin levels 
recorded both before (up to one year) and after (up to six months) drug initiation. We will calculate and 
compare mean haemoglobin change following ACEI/ARB or CCB initiation. We will use logistic regression 
to identify risk factors associated with a fall in haemoglobin after drug initiation. Risk factors considered 
will include: age, sex, ACEI/ARB or CCB use, chronic comorbidities (diabetes mellitus, cardiac failure, 
chronic kidney disease, hypertension, ischaemic heart disease, myeloproliferative syndromes, and 
chronic lung disease), pre-initiation haemoglobin level, past history of gastrointestinal bleeding, 
medications and lifestyle factors (smoking, alcohol intake, and body mass index). We will also: (1) 
Investigate whether baseline haemoglobin level and chronic kidney disease modify the effect of 
ACEI/ARBs on haemoglobin; (2) Compare change in haemoglobin between new users of ACEIs and ARBs 
by comparing mean change in haemoglobin and calculating the odds of a fall in haemoglobin in each 
group; and (3) Compare the proportion of ACEI, ARB and CCB users with records indicating post-initiation 
bone marrow suppression. 
D. Objectives, Specific Aims and Rationale 
The overall aim of the study is to investigate the association between ACEI/ARB initiation and 
subsequent reduction in haemoglobin. Specifically, we aim to: 
1. In a group of new users of ACEI/ARB and CCBs, calculate the mean change in haemoglobin after 
drug initiation and compare the result between the two groups. 
2. Compare the odds of a post-drug initiation reduction in haemoglobin of 1g/dL or more in those 
initiating ACEI/ARB with those initiating a CCB, and identify the risk factors associated with a 
reduction in haemoglobin following drug initiation. Risk factors considered will include: age, sex, 
ACEI/ARB or CCB use, chronic comorbidities (diabetes mellitus, cardiac failure, chronic kidney 
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Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
disease, hypertension, ischaemic heart disease, myeloproliferative syndromes, and chronic lung 
disease), history of gastrointestinal bleeding, medications (including warfarin, new oral 
anticoagulants, aspirin, clopidogrel, tacrolimus, cyclosporin, azathioprine, methotrexate, ferrous 
sulphate, folic acid, and B12 injections), and lifestyle factors (smoking status, alcohol intake, and 
body mass index). 
3. Investigate whether baseline haemoglobin or severe chronic kidney disease (CKD) (defined as 
estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2) modify the effect of ACEI/ARB 
initiation on haemoglobin reduction. 
4. Compare the effect on haemoglobin of ACEIs compared to ARBs by calculating mean change in 
haemoglobin and estimating the odds ratio (adjusting for confounders) of a post-drug initiation 
reduction in haemoglobin of 1g/dL or more in those on ARBs compared to those on ACEIs. 
5. Explore the relationship between ACEI/ARBs and bone marrow suppression (Read coded) by 
comparing the proportion of ACEI, ARB and CCB users with new-onset bone marrow suppression 
following drug initiation.   
The rationale for comparing the mean change in haemoglobin following initiation of an ACEI/ARB to that 
following CCB initiation (Objective 1) is to quantify the size of any haemoglobin reduction. We aim to 
compare ACEI/ARB users to CCB users as these drugs are prescribed for similar indications (thereby 
limiting confounding by indication).  
We aim to compare the odds of post-drug initiation reduction in haemoglobin of 1g/dL or more (chosen 
as a clinically meaningful reduction in haemoglobin) in those initiating each drug (Objective 2) in order 
to investigate the strength of the association while accounting for potential confounders. This will also 
allow us to identify risk factors for the association, which will offer insight into high-risk patients who 
may need close haemoglobin monitoring on initiating these drugs. 
The effect of ACEI/ARBs may be modulated by haemoglobin level prior to initiating an ACEI/ARB; the 
mechanism through which ACEI/ARBs are thought to influence haemoglobin is by inhibition of the action 
of erythropoietin (a hormone produced by the kidney that stimulates red cell production). We would 
therefore anticipate that ACEI/ARBs will cause a greater reduction in haemoglobin for people with high 
baseline haemoglobin, where baseline erythropoietin levels are likely to be normal or high (however, we 
may also find the alternative, as those with a normal or high erythropoietin may have sufficient 
erythropoietin reserve to be relatively unaffected by the [potentially small] effect of ACEI/ARB). We 
therefore aim to investigate whether baseline haemoglobin modifies the effect of ACEI/ARBs (Objective 
3) on post-drug initiation haemoglobin reduction. Similarly, we may expect to see a different effect for 
people where erythropoietin levels are reduced, as occurs in advanced chronic kidney disease (CKD). We 
will therefore investigate whether severe CKD (eGFR< 30 mL/min/1.73 m2) modifies the effect of 
ACEI/ARBs on haemoglobin.  
ACEIs and ARBs inhibit the renin-angiotensin system through different mechanisms, their impact on 
haemoglobin may therefore be different. A further secondary analysis will therefore be restricted to new 
ACEI/ARB users and compare the mean change in haemoglobin and the odds of anaemia in new ACEI 
users compared to new ARB users (Objective 4). 
Bone marrow suppression (including neutropenia, agranulocytosis, aplastic anaemia, and 
thrombocytopenia) has been reported with ACEIs, to a lesser extent with ARBs, and rarely with CCBs.1 
We will therefore explore bone marrow suppression as a potential factor in ACEI/ARB related anaemia 
by exploring the proportion of patients prescribed each class of drug with records indicating bone 
marrow suppression following drug initiation (Objective 5). 
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Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
E. Study Background 
Angiotensin converting enzyme inhibitors and angiotensin receptor blocking (ACEI/ARB) drugs are 
frequently used in the management of hypertension,2 heart failure,3 diabetic microalbuminuria, other 
proteinuric kidney diseases,4 and after myocardial infarction.5 There is evidence to suggest that these 
drugs increase the risk of anaemia.6  
Anaemia is a reduction in haemoglobin, the protein in red blood cells that carries oxygen. Anaemia is 
common in patients with a number of chronic comorbidities including heart failure,7 chronic kidney 
disease,8 and chronic inflammatory conditions.9 It causes symptoms including fatigue, weakness and 
shortness of breath and is associated with increased morbidity and mortality.7,10–14 A possible 
mechanism for the relationship between ACEI/ARBs and anaemia is through inhibition of the production 
of erythropoietin (a hormone that stimulates the production of red blood cells).15 
A meta-analysis of seven studies has estimated that ACEI/ARB users have approximately 1.6 times the 
risk of anaemia than non-users.6 However, with the exception of one study (which made a comparison 
between ACEI and ARB rather than comparing to non-users), the studies included in the meta-analysis 
were in select populations defined by cardiac or renal disease. A number of the included studies were 
also limited due to restricted adjustment for confounding, and small sample size. However, there is also 
conflicting evidence suggesting that there is either no association between ACEI/ARBs and anaemia,13,16 
or an association with an ACEI but not an ARB17 or vice versa (with an ARB but not an ACEI).18 
We therefore aim to explore the relationship between ACEI/ARBs and anaemia by investigating the 
relationship between changes in haemoglobin following drug initiation in a large group of new users of 
these drugs with no restrictions to specific disease groups.  
F. Study Type 
Hypothesis testing 
This study will test the hypotheses that: 
1. ACEI/ARB drugs reduce haemoglobin. 
2. The effect of ACEI/ARBs on haemoglobin is modified by pre-existing haemoglobin level and 
kidney function. 
3. ARBs are more strongly associated with reductions in haemoglobin than ACEIs.  
G. Study Design 
We will use a population-based cohort study to compare post drug initiation changes in haemoglobin in 
ACEI/ARB users to those in CCB users. 
H. Feasibility counts 
A feasibility count from January 2017 CPRD GOLD indicates that between January 2004 and December 
2016 there were approximately 578,160 new users of ACEI/ARB, and 464,985 new users of CCBs, who 
were at least 18 years of age and had at least 12 months of registration at their first prescription. Of the 
new ACEI/ARB users, approximately 40% (n=230,621) also had a new CCB prescription during the study 
period, while approximately 50% of the new CCB users had a new ACEI/ARB prescription.  
I. Sample size considerations 
It is unlikely that all the individuals identified by the feasibility count will be eligible for inclusion in the 
study; not all will meet CPRD quality control standards, and, more importantly, it is likely that many will 
not have both pre- and post-drug initiation haemoglobin measures (needed to establish the outcome of 
a post-initiation reduction in haemoglobin). In a previous study19 47% of new ACEI/ARB users had both 
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pre- and post-initiation serum creatinine measures (Pre: recorded up to 12 months before ACEI/ARB 
initiation; Post: recorded up to 2 months after initiation) available in CPRD. We might therefore expect a 
similar proportion of ACEI/ARB initiators to have haemoglobin monitoring available (renal function and 
full blood counts are often tested simultaneously in clinical practice), however, since haemoglobin 
monitoring on ACEI/ARB initiation is not included in standard guidelines2 it is unlikely that we will see the 
proportions for new ACEI/ARB users with both pre- and post-initiation haemoglobin measures as high as 
47%. These figures are likely to be lower again in CCB users where there is no recommended blood test 
monitoring on initiation. We have therefore assumed a conservative estimate of 20% of new ACE/ARB or 
CCB users with records of haemoglobin measures recorded at appropriate time points before and after 
drug initiation (Pre: recorded up to one year before ACEI/ARB initiation; Post: recorded up to six months 
after initiation). Using this cautious estimate of 20% of new-users with valid haemoglobin test results, 
with a figure of 230,000 new users of each class of drugs (230,000 chosen as the smallest number of new 
users of either class of drugs who were prescribed only an ACEI/ARB or a CCB during the study period; 
while we intend to identify exposure based on new prescription for each class of drugs regardless of any 
existing prescriptions [see Section M] we have used a cautious estimate of sample size here to allow for 
some patients not being eligible for inclusion) results in a cautious estimate of 46,000 individuals in each 
drug exposure group, which we have further rounded down to 40,000 to offer a conservative estimate of 
80,000 eligible individuals in total included in the study population. 
At this stage we cannot be sure how many individuals will experience a reduction in haemoglobin 
following ACEI/ARB/CCB initiation. Nor are we able to state with confidence what effect size we expect 
to detect. Table 1 therefore gives estimates of power under a range of assumptions, based on a 
conservative 1:1 comparison between ACEI/ARB and CCB users. Under a range of different assumptions, 
we will have adequate power (90% or more) to detect a difference in the odds of a reduction in 
haemoglobin between ACEI/ARB and CCB users of 1.2 or more. 
Table 1: Estimates of power to detect a range of possible odds ratios, under a range of assumptions for incidence of a fall in 
haemoglobin – assuming a conservative estimate of 80,000 new users of ACEI/ARB / CCBs. 
 Incidence of a fall in haemoglobin* 
Odds ratio 1% 2% 4% 6% 
1.1 28% 49% 77% 90% 
1.2 76% 96% >99% >99% 
1.3 98% >99% >99% >99% 
1.4 >99% >99% >99% >99% 
Calculations were done in Stata using the ‘power twoproportions’ command.  
Assuming: i) Alpha=0.05; and ii) 1:1 comparison between ACEI/ARB and CCB users. 
*We cannot be sure of the how many cases of post-initiation haemoglobin reduction will occur during ACEI/ARB or CCB exposure. However, previous studies 
have estimated incidence of anaemia in the elderly population at between 1 and 6%.20 Since clinical reasoning and previous studies21 suggest that the 
majority of antihypertensive users are over 60, it seems reasonable to think that we would see a similar level of anaemia in this population. Therefore, we 
have used a range of potential estimates of anaemia (from 1 to 6%) to represent the base rate of anaemia we might expect for a population of 
antihypertensive users and attributed this to the comparison population (i.e. CCB users). However, these are likely to be conservative estimates of outcome 
incidence given that our outcome is a fall in haemoglobin rather than a more strict diagnosis of anaemia (defined by WHO guidelines22 as haemoglobin <12 
g/dL in women or <13 g/dL in men) we would therefore expect to identify more cases of our outcome (fall in haemoglobin) than of incident anaemia, 
resulting in higher power to detect smaller effect sizes. 
 
J. Data Linkage Required (if applicable):§ 
§Please note that the data linkage/s requested in research protocols will be published by the CPRD as part of its transparency policy 
Hospital Episode Statistics – admitted patient care 
We will use Hospital Episode Statistics (HES) in-patient data in sensitivity analyses to improve the 
completeness of chronic comorbidity diagnoses (used as covariates), and with an alternative outcome 
definition using primary care coding and hospital admissions recorded with codes for anaemia. In these 
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sensitivity analyses we will restrict the study population to those eligible for HES linkage. 
Hospital Episode Statistics – outpatient 
We will use HES outpatient data in a sensitivity analysis (limited to those eligible for HES linkage) as part 
of an algorithm to identify individuals who may be managed with exogenous erythropoietin. 
K. Study population 
The source population for this study will be all patients aged 18 years or over, who meet both patient- 
and practice-level CPRD quality control standards, during the study period (January 2004 to December 
2016 – the study will run from 2004 because CKD status is important in this study and serum creatinine 
testing was more frequent after 2004 in response to the introduction of the Quality and Outcomes 
framework. If more recent data becomes available during the lifespan of the project, we will extend the 
end date of the study to maximise sample size and follow up). From the source population we will select 
all patients who are new users of ACEI/ARBs or CCBs. To capture incident ACEI/ARB / CCB users we will 
exclude those without at least 12 months of up-to-standard registration prior to their first ACEI/ARB / 
CCB prescription. We will only include those new users of ACEI/ARB / CCB with haemoglobin levels 
recorded both before (i.e. within 12 months) and after (i.e. within six months – chosen because the 
lifespan of a red blood cell is approximately 115 days23) drug initiation. 
To ensure that we have reliable measures of drug use and baseline covariates, we will check that all 
participants have at least one year of continuous registration in CPRD before entry into the study (i.e. at 
new ACEI/ARB / CCB prescription). Patients will be eligible to enter the cohort from the latest of: i) date 
practice reached CPRD quality control standards; ii) 18th birthday; or iii) one year after practice 
registration date (to ensure reliable measures of baseline health status). Patients will no longer be 
eligible for inclusion, and therefore censored, at the earliest of: i) date of death; ii) patient transferred 
out of practice; or ii) last data collection from practice. 
L. Selection of comparison group(s) or controls 
We will define comparison groups within the cohort according to exposure status (see Sections M and N 
below) – we will compare ACEI/ARB users to users of CCBs. 
M. Exposures, Health Outcomes§ and Covariates  
§Please note: Summary information on health outcomes (as included on the ISAC application form above) will be published on CPRD’s website as part of its 
transparency policy 
 
Preliminary code lists for all variables are included in the Appendix (Excel workbook). 
Exposures 
Exposure to ACEI/ARB or CCBs will be defined using recorded prescribing information. We will calculate 
the duration of prescriptions using the quantity of medication prescribed and the daily dose recorded; 
when these data were not available we will assume the population practice-level mode prescription 
duration (From past experience of ACEI/ARB / CCB prescribing in CPRD, the majority of prescriptions last 
30 days). We will assume exposure to medications starts on the date of the prescription. We will 
construct continuous courses of therapy by allowing for a 60-day gap between consecutive prescriptions 
(60 days or less between end of one prescription and start of the next) to allow for stock piling of drugs 
and non-adherence. We are interested in changes in haemoglobin on initiation of a drug, we will 
therefore determine exposure regardless of concomitant prescribing, for example if a patient with a new 
CCB prescription is already prescribed an ACEI/ARB, we will classify them as exposed to a CCB in relation 
to any change in haemoglobin in the six months after commencing the CCB. Patients may therefore 
appear up to two times in the analysis if they have a new prescription for both an ACEI/ARB and a CCB, 
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separated by at least six months (interval used to assess the outcome), during the study period.  
 
Outcomes 
The main outcomes will be change in haemoglobin level and reduction in haemoglobin of 1g/dL or more. 
We will identify the most recent haemoglobin result recorded in the 12 months before and the day of 
ACEI/ARB / CCB initiation, and a post-initiation result recorded in the six months following drug 
initiation.  
Where more than one measure of post-initiation haemoglobin has been recorded we will use the result 
closest to 115 days after drug initiation. This is the approximate life span of a red cell23 and the period at 
which you would expect to see maximal change in haemoglobin attributable to the medication. Change 
in haemoglobin will be defined as the difference between pre- and post-initiation haemoglobin results. 
In the main analysis we will define the outcome as a reduction in haemoglobin of 1g/dL or more 
(considered to be a clinically meaningful haemoglobin change).  
We will also use new-onset anaemia as an outcome in a sensitivity analysis, it will be defined according 
to WHO guidelines22 as haemoglobin <12 g/dL in women or <13 g/dL in men. As a sensitivity analysis we 
will also define the outcome as a morbidity code for anaemia recorded in CPRD and/or HES (see Section 
N). 
As a secondary analysis we will compare the proportion of ACEI, ARB and CCB users recorded with a 
post-initiation morbidity code indicating bone marrow suppression. Codes indicating bone marrow 
suppression will include codes for: neutropenia, leukopenia, thrombocytopenia, agranulocytosis, and 
aplastic anaemia. We will initially explore codes recorded within twelve months of drug initiation, 
however, these are likely to be rare outcomes so we will also look at any post drug initiation coding. 
Covariates 
We will explore the following variables as potential confounders or effect modifiers: age, sex, calendar 
period, chronic comorbidities (diabetes mellitus, hypertension, ischaemic heart disease, cardiac failure, 
CKD, myeloproliferative syndromes, and chronic lung disease), pre-initiation haemoglobin, pre-initiation 
history of gastrointestinal bleeding, other medications that may lead to changes in haemoglobin levels 
(including: warfarin, new oral anticoagulants, aspirin, clopidogrel, tacrolimus, cyclosporin, azathioprine, 
methotrexate, ferrous sulphate, folic acid, and B12 injections) and lifestyle factors (smoking status, 
alcohol intake and body mass index [BMI]). 
We will include calendar period (2004–2006, 2007–2009, 2010–2012, 2013-2015, and 2016-2017) as a 
covariate to adjust for the many changes in clinical, diagnostic and administrative practices over the 
study period that may influence the measurement of baseline renal function and other covariates. 
Baseline CKD status will be defined as eGFR <30 mL/min/1.73 m2 (i.e. severe CKD) calculated from the 
most recent serum creatinine result recorded in the 12 months prior to drug initiation using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.24 Individuals with no recorded serum 
creatinine result in the 12 months prior to drug initiation will be assumed to have no CKD.  
Diabetes mellitus, cardiac failure, hypertension, ischaemic heart disease, myeloproliferative disorders, 
chronic lung disease, history of gastrointestinal bleeding, and lifestyle factors will be identified using 
Read codes recorded in CPRD prior to first ACEI/ARB / CCB prescription. We will use existing morbidity 
code lists and algorithms for smoking status, alcohol intake, and BMI.25,26 
Pre-drug initiation haemoglobin will be defined as the most recent recorded haemoglobin level in the 
year before drug initiation. 
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We will use prescribing data to identify exposure to other medications that may lead to changes in 
haemoglobin levels (including: warfarin, new oral anticoagulants, aspirin, clopidogrel, tacrolimus, 
cyclosporin, azathioprine, methotrexate, ferrous sulphate, folic acid, and B12 injections). We will identify 
exposure to these medications at the time of ACEI/ARB or CCB prescription by using prescription data to 
construct courses of continuous therapy using a similar approach to that taken to identify ACEI/ARB / 
CCB exposure (i.e. We will calculate the duration of prescriptions using the quantity of medication 
prescribed and the daily dose recorded. We will assume exposure to medications starts on the date of 
the prescription and allow for a 60-day gap between consecutive prescriptions). 
N. Data/ Statistical Analysis 
Main analysis 
We will present descriptive statistics comparing the following variables between new ACEI/ARB and CCB 
users: age, sex, chronic comorbidities (diabetes mellitus, cardiac failure, CKD), pre-initiation 
haemoglobin, history of gastrointestinal disease, and lifestyle factors (smoking, alcohol and BMI). We 
will calculate the mean drop in haemoglobin following drug initiation in new ACEI/ARB and CCB users 
and compare the results using t-tests. We will use logistic regression to compare the odds of new-onset 
reduction in haemoglobin of 1g/dL or more in ACEI/ARB users compared to CCB users. We will construct 
an age and sex adjusted model with just the main exposure variable (ACEI/ARB / CCB), age and sex, 
followed by a model adjusting for potential confounders informed by a priori knowledge including the 
following covariates age, sex, chronic comorbidities (cardiac failure, diabetes mellitus, hypertension, 
ischaemic heart disease, CKD), calendar period, and history of gastrointestinal bleeding and using robust 
standard errors to account for clustering by general practice. Finally, we will fit a fully adjusted model 
additionally adjusting for smoking, alcohol intake, and BMI (we will not adjust for these initially as we 
believe much of their effect will be captured by chronic comorbidities). 
To ensure confidentiality, any cells containing <5 events will be suppressed in results. All data 
management and analyses will be performed using Stata version 14 (StataCorp, Texas). 
Sensitivity analyses 
We will test how robust our findings are by repeating the main analysis after: 
1. Varying the time used to identify pre-initiation haemoglobin: It could be argued that a 
haemoglobin result recorded up to 12 months prior to drug initiation does not reflect the actual 
haemoglobin level prior to initiation, we will therefore repeat the main analysis in those with a 
pre-initiation haemoglobin result recorded in the month (we will extend this to 3 or 6 months if 
sample size becomes unfeasible) before ACEI/ARB initiation.  
2. Excluding those whose post-initiation haemoglobin is recorded in the first four weeks following 
drug initiation: Blood test results recorded shortly after starting the drugs may not reflect the true 
response to them. To test the impact of this, we will repeat the main analysis after excluding 
individuals with early (i.e. within four weeks) post-initiation haemoglobin records. 
3. Accounting for concomitant prescribing of ACEI/ARB and CCBs: For individuals with a new 
prescription for both classes of drug (ACEI/ARB and CCB) separated by less than six months 
(interval used to assess outcome) it may be difficult to determine which drug is responsible for 
any observed changes in haemoglobin (here the unit of analysis is the drug class prescribed for 
the individual [hence one individual may contribute two observations – for both ACEI/ARBs and 
CCBs – to the analysis] rather than the individual). However, it would be inappropriate to drop 
these individuals (with prescriptions for both classes of drugs within six months) from the main 
analysis as this would systematically exclude sicker individuals. Therefore, in the main analysis we 
will not include exposure to the second drug if it is prescribed within six months of the start of the 
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first prescribed class of drugs. This approach may bias the effect estimate to the null; a fall in 
haemoglobin caused by the second class of drugs prescribed may be wrong attributed to the first 
class of drugs prescribed. However, this approach would mean that we would be unlikely to 
overestimate any association observed between the drugs and the outcome. To assess the impact 
of this approach we will conduct a sensitivity analysis without dropping the second prescription 
event from the analysis (i.e. including exposure to a second class of drugs prescribed within six 
months of the first). To test our exposure definition further, we will also conduct another 
sensitivity analysis where we exclude new users of one class of drugs who are prevalent users of 
the other class. For example, we will exclude new users of ACEI/ARBs who are already prescribed 
a CCB at the time of their first ACEI/ARB prescription. This will ensure that any effect we observe 
is due to the newly prescribed medication and not the existing drug. 
4. Limiting to individuals with known CKD status: Serum creatinine testing is more likely in those who 
are acutely unwell, or routinely monitored as part of incentivised programs (e.g. diabetics). 
Therefore, to avoid selection bias in the main analysis we will assume that individuals with no 
serum creatinine result recorded within the 12 months prior to ACEI/ARB / CCB initiation have no 
CKD. To test the impact of this assumption, we will repeat the analysis only in those with known 
CKD status (identified using most recent serum creatinine result recorded in the 12 months prior 
to drug initiation). 
5. Defining the outcome as new-onset anaemia: We have chosen to use what we believe to be a 
clinically meaningful decrease in haemoglobin of 1g/dL as the outcome in the main analysis. 
However, it would also be useful to investigate the risk of new-onset anaemia following drug 
initiation. We will therefore repeat the main analysis defining the outcome as new-onset anaemia 
according to WHO guidelines22 as haemoglobin <12 g/dL in women or <13 g/dL in men. 
6. Including all new-users of ACEI/ARB / CCB regardless of haemoglobin records and defining 
reduction in haemoglobin as coded anaemia: By restricting our study population to individuals 
with pre- and post-initiation haemoglobin levels we may have selected a population of sicker 
individuals (haemoglobin testing is more likely in those with clinical need), we will therefore 
include all eligible new users regardless of haemoglobin records and define the outcome as 
anaemia coded in CPRD records within twelve months of drug initiation. We will also run this 
analysis restricted to those eligible for HES linkage and define anaemia coded in both primary care 
and hospital records. 
7. Limiting to practices consenting to HES linkage (and study period ending March 2016, i.e. the 
latest date for HES linkage) and defining covariates using both primary-care and hospital 
admission coding: Completeness of chronic comorbidity identification can be improved by using 
hospital admissions data,27 however, this will limit sample size as only 58% of CPRD practices have 
consented to data linkage28  therefore we will only undertake this as a sensitivity analysis.  
8. Excluding patients with cardiac failure or taking diuretics: Cardiac failure and diuretics may lead to 
changes in blood haemoglobin concentration through their action on fluid balance (resulting in 
changes in the relative amount of blood plasma to red blood cells, see Section S).29 We will 
therefore test whether changes in blood concentration impact our findings by repeating our main 
analysis after: (1) excluding those with cardiac failure; (2) excluding those also prescribed a 
diuretic; and (3) excluding all those either prescribed a diuretic or with a diagnosis of cardiac 
failure. 
9. Excluding patients who may be managed with exogenous erythropoietin: Some individuals with 
anaemia secondary to CKD may be managed with exogenous erythropoietin. Including these 
individuals in our analysis may influence our results as the effect of ACEI/ARBs on haemoglobin is 
thought to be mediated via erythropoietin. We are unable to identify those managed with 
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erythropoietin using primary care prescribing data as erythropoietin prescribing for renal anaemia 
is usually managed by nephrologists. We will therefore run a sensitivity analysis limiting to those 
eligible for HES linkage and excluding those with serum creatinine test results indicating CKD stage 
4 or above (eGFR<30) whose CKD is managed by nephrologists (identified using HES outpatient 
data). 
10. Propensity score matched cohort: We will develop a propensity score matched cohort to ensure 
that we are comparing similar groups of ACEI/ARB and CCB users. We will use logistic regression 
to calculate propensity scores predicting choice of ACEI/ARB or CCB treatment. Factors included in 
the propensity score model will include all covariates adjusted for in the main analysis. Patients 
receiving ACEI/ARBs and patients receiving CCBs will be assigned to matched sets (using optimal 
propensity score matching) according to the value of their propensity score so that at least one 
patient from each treatment group is included in each set.30,31 We will measure standardised 
differences for each covariate to check for balance between groups, before estimating the odds 
ratio comparing odds of a reduction in haemoglobin in ACEI/ARB users with that in the matched 
cohort of CCB users. 
Secondary analyses 
As secondary analyses we will investigate the impact of including interactions between: 1) ACEI/ARB and 
baseline (pre-initiation) haemoglobin; and 2) ACEI/ARB and CKD status.     
We will also compare the effect on haemoglobin of ACEIs compared to ARBs by calculating mean change 
in haemoglobin and estimating the odds ratio (adjusting for confounders) of a fall in haemoglobin of 
1g/dL or more in those starting ARBs compared to those starting ACEIs. 
Finally, we will investigate the effect of ACEIs, ARBs, and CCBs on bone marrow suppression. Bone 
marrow suppression is likely to be a rare outcome; therefore, rather than an adjusted regression 
analysis, we will only compare the proportion of individuals recorded with codes indicating bone marrow 
suppression after drug initiation in each group (ACEI, ARB and CCB). In this analysis we will investigate 
ACEI and ARB users separately as it is possible that these drugs will have different effects on bone 
marrow.  
O. Plan for addressing confounding 
We will limit confounding by indication by comparing the effect of ACEI/ARBs on haemoglobin to a class 
of drugs that are prescribed for similar indications (CCBs). We will use multivariable logistic regression to 
adjust for the potential confounders (listed in Section M), and check these results with results from a 
propensity score matched cohort (see Section N). 
P. Plans for addressing missing data  
We expect patients prescribed ACEI/ARBs or CCBs are likely to have health risk factors considered when 
their medications are prescribed so, based on our experience with recent studies, we do not anticipate 
missing data to be a major problem. We will therefore undertake a complete case analysis unless 
missing data is greater than 30%, when we will undertake further sensitivity analyses. For example, if 
necessary to reduce any selection biases due to missing data, we will repeat the main analysis restricting 
it to more recent calendar periods when data may be more complete (due to improvements in data 
quality following changes in lab reporting and incentives offered by the Quality and Outcomes 
Framework). 
Q. Patient or user group involvement (if applicable) 
Patients have not yet been involved in the planning of this study. We aim to share important findings 
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with patient representatives. It is hoped that these patient representatives will help plan further 
dissemination and use of the results. 
R. Plans for disseminating and communicating study results, including the presence or absence of any restrictions on the 
extent and timing of publication  
We intend to publish our findings in peer-reviewed scientific journals, and to present them at relevant 
scientific meetings (including the International Conference on Pharmacoepidemiology & Therapeutic 
Risk Management). 
S. Limitations of the study design, data sources, and analytic methods  
The internal validity of our study is, similar to other observational studies, potentially limited by 
selection and information bias, and confounding. The study is population-based and not restricted to 
specific demographic, hospital, or insurance groups. Hence, selection bias may not a major concern. 
However, because routine haemoglobin monitoring is not included in guidelines for ACEI/ARB or CCB 
prescribing, we may find that (because we require both pre- and post-initiation haemoglobin levels) 
those eligible for inclusion in the study may be a group of potentially sicker individuals (as haemoglobin 
testing is more likely in those with clinical need). It is hoped that this selection bias is not different in 
those prescribed an ACEI/ARB compared to those prescribed a CCB, so there should be limited influence 
on the effect estimate, but the results may not be generalizable to all ACEI/ARB / CCB users. Therefore, 
we will repeat the main analysis including all eligible new users of ACEI/ARBs or CCBs regardless of 
whether they have haemoglobin results recorded and define the outcome as recorded anaemia 
morbidity codes rather than percentage reduction in haemoglobin. 
A number of studies have linked CCBs (our comparison group) to a reduction in haemoglobin (through 
increased risk of gastrointestinal bleeding)32–34, however, other studies have provided no evidence for 
this link.32 If there is indeed a link between CCBs and subsequent haemoglobin reduction, our 
comparison group may also show a change in haemoglobin following drug initiation. This may limit our 
ability to demonstrate an association of ACEI/ARBs with reduced haemoglobin levels. However, our 
choice of comparison group is limited, we need to compare ACEI/ARBs to drugs that are prescribed for 
similar indications. If we do not, any differences we see could be explained by the reason the drug is 
prescribed rather than the drug itself. Therefore, in this context, while flawed, CCBs remain the best 
choice, and since the mechanism through which ACEI/ARBs (via erythropoietin) and CCBs (via 
gastrointestinal bleeding) are thought to lead to anaemia are different, it is hoped that by adjusting for 
confounders (particularly gastrointestinal bleeding and baseline renal function) and some of our 
secondary analyses (looking at interactions between ACEI/ARB and baseline haemoglobin or renal 
function) will provide insight into differences between ACEI/ARBs and CCBs. Further, any results will help 
inform drug choice in situations where there is currently equipoise between choice of an ACEI/ARB or a 
CCB. 
Haemoglobin levels may be influenced by how much fluid there is in the body. If the volume of plasma in 
relation to the number of red blood cells changes then haemoglobin may be artificially changed. For 
example, the blood may become concentrated (haemoconcentration) due to loss of plasma or water 
when a patient is dehydrated or has burns resulting in an artificially high haemoglobin. Conversely, there 
may be an increase in the fluid content of blood, for example in cardiac failure or pregnancy, leading to a 
lower concentration of red blood cells (haemodilution) and therefore a decrease in haemoglobin. Our 
results may therefore be influenced by a patient’s fluid balance. This is important because ACEI/ARBs or 
CCBs are used to manage cardiac failure (which causes water retention due to the heart’s inability to 
pump blood efficiently), and patients prescribed ACEI/ARBs or CCBs are also likely to be managed with 
diuretics (which act by reducing blood circulating volume by increasing the production of urine) meaning 
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that any reduction in haemoglobin may be as a result of changes in fluid balance rather than actual 
changes in the total amount of haemoglobin in the blood. To test any impact on our findings resulting 
from changes in fluid balance rather than real changes in haemoglobin we will conduct a sensitivity 
analysis by repeating the main analysis after excluding all those prescribed a diuretic or with a diagnosis 
of cardiac failure. 
Some individuals with anaemia secondary to CKD may be managed with exogenous erythropoietin. 
Including those managed with exogenous erythropoietin may influence our results as the effect of 
ACEI/ARBs on haemoglobin is thought to be mediated via erythropoietin. While we do not expect this to 
affect many individuals (and therefore the effect of including those treated with exogenous 
erythropoietin should be minimal), we will nonetheless test the impact of their inclusion by running a 
sensitivity analysis excluding those who may be treated with exogenous erythropoietin (see Section N).  
There may be misclassification of ACEI/ARB / CCB exposure; a prescription does not guarantee a patient 
takes a drug. We anticipate that our estimate of drug exposure will be flawed to some extent due to lack 
of adherence. Since this is unlikely to be differential for different drugs, it will be unlikely to influence the 
results of the study. 
We hope that any misclassification due to variability in coding practices will be mitigated by adjustment 
for calendar period (to account for temporal changes in diagnostic and coding practices), careful 
development of code lists and, where possible, use of previously validated code lists. In addition, robust 
standard errors will be used to account for clustering by general practice. 
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Amendments to protocols approved by ISAC    Version June 2015 
During the course of some studies, it may become necessary to deviate from a protocol which has been approved by 
ISAC. Any deviation to an ISAC approved protocol should be clearly documented by the applicant but not all such 
amendments need be submitted for ISAC review and approval. The general principles to be applied in regard to the 
need for submission are as follows: 
• Major amendments should be submitted 
• Minor amendments need not be submitted (but must still be documented by the applicant and should 
normally be mentioned at the publication stage) 
 
In cases of uncertainty, the applicant should contact the ISAC secretariat for advice quoting the original reference 
number and providing a brief explanation of the nature of the amendment(s) and underlying reason(s). 
 
Major Amendments 
We consider an amendment as major if it substantially changes the study design or analysis plan of the proposed 
research. An amendment should be considered major if it involves the following (although this is not necessarily an 
exhaustive list): 
• A change to the primary hypothesis being tested in the research 
• A change to the design of the study 
• Additional outcomes or exposures unrelated to the main focus of the approved study* 
• Non-trivial changes to the analysis strategy  
• Not performing a primary outcome analysis 
• Omissions from the analysis plan which may impact on important validity issues such as confounding 
• Change of Chief Investigator 
• Use of additional linkages to other databases 
• Any new proposal involving contact with health professionals or patient or change in regard to such matters 
 
* N.B. extensive changes in this respect will require a new protocol rather than an amendment - if in doubt please 
consult the Secretariat 
 
Minor Amendments 
Examples of amendments which can generally be considered minor include the following: 
• Change of personnel other than the Chief Investigator (these should be notified to the Secretariat) 
• A change to the definition of the study population, providing the change is mentioned and justified in the 
paper/output [NB previously major] 
• Extension of the time period in relation to defining the study population 
• Changes to the definitions of outcomes or exposures of interest, providing the change is mentioned and 
justified in the paper/output [NB previously major] 
• Not using linked data which are part of the approved protocol, unless the linked data are considered critical 
in defining exposures or outcomes (in which case this would be a major amendment) 
• Limited additional analysis suggested by unexpected findings, provided these are clearly presented as post-
hoc  
• Additional methods to further control for confounding or sensitivity analysis provided these are to be 
reported as secondary to the main findings 
• Validation and data quality work provided additional information from GPs is not required 
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To submit an amendment of protocol to the ISAC, please submit the following documents to the ISAC mailbox 
(isac@cprd.com)  
1. A covering letter providing justification for the request  
2. A completed and, if necessary, updated application form with all changes highlighted; if new linkages are required 
the current version of the ISAC application form must be completed. Otherwise, the original form may be amended 
as necessary 
3. The updated protocol document containing the heading 'Amendment' at the end of it. Please include all 
amendments to the protocol under this heading. No other changes should be made to the already approved 
document.  
 
 
 
